Crossject organisera un webcast le 6 février à 17h30 pour faire le point sur sa stratégie commerciale
February 01, 2024 12:15 ET
|
CROSSJECT
Dijon, France, 1 février 2024 – 18 : 15 CET - Crossject (ISIN : FR0011716265 ; Euronext : ALCJ), une société pharmaceutique spécialisée qui développe des auto-injecteurs sans aiguille dédiés aux...
Crossject to host a business briefing on commercial strategy on February 6 at 17:30 CET
February 01, 2024 12:15 ET
|
CROSSJECT
Dijon, France, February 1, 2024 -- 18:15 CET - Crossject (ISIN: FR0011716265; Euronext: ALCJ), a specialty pharma company developing needle-free auto-injectors for emergency situations, will hold a...
Vagus Nerve Stimulator Market is Poised to Thrive at CAGR of 10.1% During 2022-2031 | TMR Study
April 17, 2023 16:30 ET
|
Transparency Market Research
Wilmington, Delaware, United States, April 18, 2023 (GLOBE NEWSWIRE) -- The global vagus nerve stimulator market size was worth USD 444.7 Mn in 2021 and is anticipated to exceed value of USD 1.1 Bn...
Stopping Epilepsy Before It Starts? CURE Researcher Identifies a Possible Biomarker
February 06, 2018 09:50 ET
|
About Citizens United for Research in Epilepsy (CURE)
Chicago, Feb. 06, 2018 (GLOBE NEWSWIRE) -- New research, funded by Citizens United for Research in Epilepsy (CURE), has discovered a ‘smoking gun’ biomarker that could result in treatments that stop...